KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $18.2 million.

  • Castle Biosciences' Net Income towards Common Stockholders fell 122.08% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 300.86%. This contributed to the annual value of $18.2 million for FY2024, which is 131.75% up from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Net Income towards Common Stockholders is $18.2 million, which was up 131.75% from -$57.5 million recorded in FY2023.
  • Castle Biosciences' 5-year Net Income towards Common Stockholders high stood at $18.2 million for FY2024, and its period low was -$67.1 million during FY2022.
  • In the last 3 years, Castle Biosciences' Net Income towards Common Stockholders had a median value of -$57.5 million in 2023 and averaged -$35.5 million.
  • Per our database at Business Quant, Castle Biosciences' Net Income towards Common Stockholders tumbled by 443.83% in 2020 and then surged by 131.75% in 2024.
  • Over the past 5 years, Castle Biosciences' Net Income towards Common Stockholders (Yearly) stood at -$10.3 million in 2020, then plummeted by 204.28% to -$31.3 million in 2021, then plummeted by 114.55% to -$67.1 million in 2022, then rose by 14.41% to -$57.5 million in 2023, then skyrocketed by 131.75% to $18.2 million in 2024.